



11/04/05 | Press Release

DAVA Pharmaceuticals, Inc. Completes Acquisition of VoSpire ER®

Fort Lee, New Jersey, November 4, 2005 -- DAVA Pharmaceuticals, Inc. ("DAVA") announced today that it has completed the acquisition of VoSpire ER® pursuant to its Asset Purchase Agreement with Odyssey Pharmaceuticals, Inc., a subsidiary of PLIVA d.d. VoSpire ER® is the only albuterol extended release tablet indicated for the treatment of bronchospams associated with reversible airway disease.

With the closing of the acquisition, DAVA will begin accepting and fulfilling orders for VoSpire ER®. DAVA has product available for immediate and consistent delivery. For more information contact DAVA at 1-866-947-DAVA (3282).

About DAVA Pharmaceuticals

DAVA Pharmaceuticals, a specialty pharmaceutical company, is focused on establishing and marketing a broad portfolio of pharmaceutical products. DAVA Pharmaceuticals is aggressively building its product portfolio through a combination of acquisitions, strategic alliances in-licensing transactions, partnerships and development. For further information, please visit DAVA's website, located at www.davapharma.com.